Benmelstobart plus anlotinib as first treatment for older people with advanced lung cancer
Tests benmelstobart with anlotinib, without chemotherapy, in older people with advanced non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
Key facts
- Where
- Hangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 75 or older with non-small cell lung cancer that has spread or cannot be removed, who have not had treatment before and cannot or will not have chemotherapy or radiotherapy.
- Age
- 75 years or older (the registry field reads 75 Days, but the criteria say 75 years)
- Sex
- Women and men can join.
- Disease stage
- Non-small cell lung cancer that cannot be removed by surgery and is locally advanced (Stage IIIB/IIIC) or has spread (Stage IV), with at least one tumour that can be measured. Brain metastases are allowed.
- Earlier treatment
- The trial is looking for people who cannot have, or refuse, chemotherapy and radiotherapy given together or one after the other.
- Biomarker or test result
- No EGFR sensitive mutation and no ALK gene change. Squamous cancer with unknown status counts as negative and needs no test.
Main reasons for not taking part
- Small cell lung cancer components in the tumour
- A cancer gene change that standard targeted therapy can treat
- Active autoimmune disease treated with systemic medicine in the past 2 years, or a positive HIV test
- History of organ or stem cell transplant
- Brainstem, meningeal or spinal cord metastases, or serious heart, bleeding or blood clot problems
Read by machine on 12 November 2026.
Where in China
- Zhejiang Cancer HospitalHangzhou, ChinaContact: Yanjun Xu, M.D.No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zhejiang Cancer Hospital
- Trial code
- NCT07849712
- Record updated
- 30 September 2026
- Original description
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).Read full original descriptionShow less
Bemo-sufail Monoclonal Antibody Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer: An Exploratory Clinical Study
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).